Raumedic, a German developer and supplier of polymer-based components to the medical device and pharmaceutical industry, is restructuring its business units.
The firm's current three business units will now become two.
Extruded tubing operations will continue to be coordinated within the Tubing business unit, managed by Ralf Ziembinski, while injection moulding components and their subsequent processing into modules and systems will be housed within the new Systems business unit. Thomas Knechtel, who was previously responsible for the assembly unit and the development of catheters, will now manage this unit.
Raumedic says the restructure will help the firm to ensure that all expertise concerning the development and production of complex system products is centralised in one business unit and also improve efficiency.
'This new structure guarantees that the technology, quality and service that we as a polymer specialist for the medical engineering and pharmaceutical industry offer, will also in future be highly qualified and quickly available for our customers and their product ideas,' says Martin Bayer, Managing Director of Raumedic.
Thomas Knechtel will manage the new Systems business unit
The technologies include micro- and multi-component injection moulding, insertion moulding, fully automated assembly facilities, extrusion of tubing (also in the micro-range), and film blowing.
With this step, Raumedic says it is strengthening its market position as a full-service supplier of polymeric products manufactured in a 10,000m2 cleanroom production area.
Over the last two years the firm has invested in the expansion and development of its locations in Europe and North America. This includes a €26m investment in the extension of its company headquarters in Helmbrechts, Bavaria, which includes areas for the administration, laboratories and logistics, as well a 2,250m2 Class 7 cleanroom production area.
In January this year, Raumedic started operations at its first US production facility in Mills River, North Carolina, in a US$27m investment.
